XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia-Reference-Cited by-同舟云学术

XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia

Published:2022-05-26 Issue:7 Volume:39 Page:3316-3333
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Liu Ping-Yen,Choi Eue-Keun,Kim Tae-Seok,Kuo Jen-Yuan,Lee Jung Myung,On Young Keun,Park Sang-Weon,Park Hyung-Wook,Shin Dong-Gu,Wang Lili,Yen Hsueh-Wei,Lee Moon-Hyoung,

Funder

Bayer HealthCare

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02102-8.pdf

Reference50 articles.

1. Andrew NE, Thrift AG, Cadilhac DA. The prevalence, impact and economic implications of atrial fibrillation in stroke: what progress has been made? Neuroepidemiology. 2013;40:227–39. https://doi.org/10.1159/000343667.

2. Pistoia F, Sacco S, Tiseo C, et al. The epidemiology of atrial fibrillation and stroke. Cardiol Clin. 2016;34:255–68. https://doi.org/10.1016/j.ccl.2015.12.002.

3. Chiang CE, Wang KL, Lin SJ. Asian strategy for stroke prevention in atrial fibrillation. Europace. 2015;17 Suppl 2:ii31–9. https://doi.org/10.1093/europace/euv231.

4. Zirlik A, Bode C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis. 2017;43:365–79. https://doi.org/10.1007/s11239-016-1446-0.

5. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. https://doi.org/10.1056/NEJMoa1009638.